Actively Recruiting

Phase Not Applicable
Age: 60Years - 80Years
All Genders
Healthy Volunteers
NCT07144527

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Led by Scott Silveira · Updated on 2026-02-20

40

Participants Needed

1

Research Sites

44 weeks

Total Duration

On this page

Sponsors

S

Scott Silveira

Lead Sponsor

C

Concordia University Chicago

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.

CONDITIONS

Official Title

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Who Can Participate

Age: 60Years - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 60 to 80 years, of any sex
  • Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
  • Normal or near-normal cardiovascular function confirmed by stress echocardiogram or coronary CT angiogram within the past 12 months showing no significant heart abnormalities
  • No new cardiovascular symptoms such as chest pain, shortness of breath, or fainting since cardiovascular testing
  • Montreal Cognitive Assessment (MoCA) score of 26 or higher
  • Free from acute or uncontrolled chronic medical conditions that could affect participation
  • Physically capable of moderate to vigorous intensity stationary cycling exercise
  • Successful completion of a graded exercise test without significant adverse events
  • Ability to attend at least four in-person laboratory visits in Beverly Hills, California
  • Non-smoker for at least 12 months
  • Able to provide informed consent and comply with study procedures
  • Willing to avoid starting new exercise, supplements, or medications during the study
Not Eligible

You will not qualify if you...

  • Severe cardiovascular disease such as recent heart attack within 6 months, unstable angina, or uncontrolled high blood pressure over 160/100 mmHg
  • Severe respiratory diseases preventing exercise participation
  • Significant neurological impairments affecting understanding or exercise ability
  • Terminal illness or conditions limiting life expectancy or study completion
  • Severe cognitive impairment preventing informed consent or participation
  • Significant orthopedic problems or injuries preventing safe exercise
  • Use of NMN, NR, or other NAD+-altering supplements within 14 weeks before the study
  • Drinking more than 2 alcoholic drinks per week or unwillingness to abstain from alcohol during the study
  • Current substance abuse affecting participation or adherence
  • Other acute or chronic health conditions that pose risk or interfere with study goals
  • Non-compliance with study requirements or withdrawal of consent
  • Any condition judged by investigators to interfere with participation or results interpretation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Medical Office of Dr. Robert Huizenga MD

Beverly Hills, California, United States, 90210

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults | DecenTrialz